Get Full Access and More at

ExpertConsult.com

Diagnostic Imaging Nuclear Medicine

SECOND EDITION









Diagnostic Imaging Nuclear Medicine

SECOND EDITION





Diagnostic Imaging

Nuclear Medicine

SECOND EDITION

Paige Bennett, MD

Associate Professor Nuclear Medicine and Molecular Imaging Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

Umesh D. Oza, MD

Diagnostic Radiology Residency Program Director Baylor University Medical Center at Dallas Clinical Associate Professor Texas A&M Health Science Center College of Medicine College Station, Texas

Andrew T. Trout, MD

Assistant Professor of Radiology and Pediatrics Department of Radiology Cincinnati Children's Hospital Medical Center Cincinnati, Ohio

Akiva Mintz, MD, PhD, MHA, CFA

Vice Chair of Finance, Department of Radiology Section Head, Nuclear Medicine and Molecular Imaging Department of Radiology and Neurosurgery Leader, Translational Imaging Program Assistant Director, Wake Forest Clinical & Translational Science Institute (CTSI) Wake Forest School of Medicine Winston-Salem, North Carolina



1600 John F. Kennedy Blvd. Ste 1800 Philadelphia, PA 19103-2899

DIAGNOSTIC IMAGING: NUCLEAR MEDICINE, SECOND EDITION

ISBN: 978-0-323-37753-9

Copyright © 2016 by Elsevier. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices	
Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.	
Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.	
With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.	
To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.	
Publisher Cataloging-in-Publication Data	
Diagnostic imaging. Nuclear medicine / [edited by] Paige Bennett and Umesh D. Oza. 2nd edition. pages ; cm	

Nuclear medicine Includes bibliographical references and index.
ISBN 978-0-323-37753-9 (hardback)
1. Diagnostic imaging--Handbooks, manuals, etc. 2. Nuclear medicine--Handbooks, manuals, etc. I. Bennett, Paige. II. Oza, Umesh D. III. Title: Nuclear medicine.
[DNLM: 1. Diagnostic Imaging--methods--Atlases. 2. Nuclear Medicine--methods--Atlases.
3. Radiopharmaceuticals--Atlases. WN 39]

RC78.7.D53 D5282 2015 616.07/57--dc23

International Standard Book Number: 978-0-323-37753-9

Cover Designer: Tom M. Olson, BA Cover Art: Richard Coombs, MS

Printed in Canada by Friesens, Altona, Manitoba, Canada

Last digit is the print number: 9 8 7 6 5 4 3 2 1



Working together to grow libraries in developing countries

www.elsevier.com • www.bookaid.org

Dedications

This book is dedicated to my family. To Diane and Ted Bennett, who love me the most. To Betsy, Sidney, and Lee Andrew Clark, the loves of my life. To my extended family of friends, Dr. Kathryn Morton, Cecilia Vargas Ortega. Nothing matters without all of you. Thank you to everyone who works with Amirsys: Your professionalism, leadership, and vision created the Diagnostic Imaging series, of which we are all proud to be a part. Arthur Gelsinger and Dr. Umesh Oza: You made this endeavor fun. Double thanks.

PB

While we have laboriously poured heart, soul, and spirit into this textbook to impart the leading edge of nuclear medical knowledge to the next generation, there has been an equally and painstaking devotion paid to us by loved ones and mentors that have dedicated time, wisdom, guidance, and advice that cannot, and should not, go unrecognized. To my beautiful wife, Komel, thank you for your strength, guidance, and unwavering resolve. To my children, Quaid and Willa, you are my driving force. I want for you what you have given me — courage to strive for better, enjoy life to the absolute fullest, and run with wild abandon. To my loving parents, Dhruv and Surekha, thank you for your lifelong sacrifice, instilling discipline and confidence and single-minded focus raising three successful children. To Rishi and Veena, thank you for your unconditional love and steadfast support. A project of this magnitude reflects the hard efforts of many underrecognized people. I extend my deepest gratitude to all of you — thank you!

UDO

Contributing Authors



Angela P. Bruner, PhD, DABR

Director, Radiation Safety Officer, Medical Physicist Radiation Safety & Medical Physics Baylor Scott & White Health - North Texas Dallas, Texas

Hollins Clark, MD

Associate Professor Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

Pushpender Gupta, MBBS

Assistant Professor Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

John M. Holbert, MD, FACR

Professor of Diagnostic Radiology Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

Brian Kouri, MD

Associate Professor Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

Shane C. Masters, MD, PhD

Assistant Professor Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

Anita Thomas, MD

Associate Professor Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

Christopher T. Whitlow, MD, PhD, MHA

Section Head, Neuroradiology Associate Professor Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

Matthew Bennett, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Todd Michael Danziger, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

James Patrick Davidson, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Trevor Downing, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Christopher R. McAdams, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Amie M. McPherson, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Virginia Barnes Planz, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina



Colin Segovis, MD, PhD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Valerie E. Stine, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Pavani Thotakura, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Paula Vergara-Wentland, MD

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Bimal Vyas, MD, MS

Department of Radiology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Amanda Jo Lott Marcellino, MD

Department of Otolaryngology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Ashley C. Mays, MD

Department of Otolaryngology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

T. Alex McKnight, MD

Department of Otolaryngology Wake Forest Baptist Medical Center Winston-Salem, North Carolina

Kelli Y. Ha, MD Department of Radiology, Breast Imaging Baylor University Medical Center Dallas, Texas

Tejaswini Vasamsetty, MD

Research Assistant Department of Radiology Wake Forest School of Medicine Winston-Salem, North Carolina

John Bailey, MD Wake Forest School of Medicine Winston-Salem, North Carolina

Aidan Burke, MD Wake Forest School of Medicine Winston-Salem, North Carolina

Daniel G. Hampton, MD Wake Forest School of Medicine

Winston-Salem, North Carolina Katarina Kesty, MD, MBA

Wake Forest School of Medicine Winston-Salem, North Carolina

Zachary Allen Lindsey, MD Wake Forest School of Medicine Winston-Salem, North Carolina

Charlotte Myers, MD

Wake Forest School of Medicine Winston-Salem, North Carolina

Bryan J. Neth, BS Wake Forest School of Medicine Winston-Salem, North Carolina

Brad Perry, MD Wake Forest School of Medicine Winston-Salem, North Carolina

G. Lance White, MD Wake Forest School of Medicine Winston-Salem, North Carolina

Preface

6

Since the publication of the first edition of Diagnostic Imaging: Nuclear Medicine, the world of nuclear medicine and molecular imaging has continued to rapidly evolve. PET/CT remains the most substantial advancement in the field in recent times, with PET/CT volumes continuing to climb. New PET/CT radiopharmaceuticals and time-of-flight technology have both become more mainstream. Astounding leaps have occurred in equipment such as with the incredible integrated PET/MR systems. Awareness of radiation dose to the patient has moved to the forefront of consciousness, and advances in software and detector equipment have helped dramatically lower radiation exposure. At the same time, many new therapies, radiotracers, and techniques push the boundaries of what is possible, showing the enduring importance of nuclear medicine in patient care.

8

10

12

The second edition reflects the changes seen in practice. Careful attention has been paid to the recent revisions in radioiodine therapy guidelines for cancer and hyperthyroidism. New chapters have been added, which cover the use of Ra-223 for the treatment of painful prostate cancer bone metastases and the use of I-123 ioflupane (DaTscan) for the diagnosis of parkinsonian syndromes. F-18 NaF PET/CT assessment for the bones is now thoroughly covered, including its indication for nonaccidental trauma in children. In addition, many of the popular quick reference tables have been added. These include easy-touse tables in the completely updated pulmonary embolism chapter and differential diagnosis tables such as in the musculoskeletal chapters.

2

2 min

14 16 18 20 22 24

In order to make this text a more complete reference and study tool, new chapters have been dedicated to nuclear medicine physics and Nuclear Regulatory Commission (NRC) guidelines. In fact, all study guide topics listed for the American Board of Radiology board exam are fully covered. A radiopharmaceutical table now provides a critical overview, covering key parameters of the important agents currently in use. While these items are especially valuable for the physician preparing to undergo recertification or certification, they are also useful for the practitioner in the field.

Certainly, this edition continues to build on the successful philosophy of its predecessor. The topic-based format allows the reader to rapidly approach cases from the most practical standpoint. Incredible images illustrate the spectrum of disease, highlight potential pitfalls in the differential diagnosis, and outline critical anatomy. Each section contains multiple new images, maintaining the high standards expected from the Diagnositc Imaging series. Bulleted text describes all the details needed, from the level of the novice to that of the expert, but keeps the focus of each section sharp. Expanded sections have been added to better cover image interpretation and exam protocol advice, making this edition even more useful as a reference in the clinic.

We are especially proud of the team assembled to compile this text. They are a group of dedicated nuclear medicine physicians and nuclear radiologists who are also gifted teachers. Under the leadership of Dr. Paige Bennett (formerly Clark) of Wake Forest University Health Sciences and Dr. Umesh Oza of Baylor University, the text continues to be carefully edited and thoughtfully developed. In short, *Diagnostic Imaging: Nuclear Medicine, Second Edition*, continues to be a musthave for any practioner in the field.

Janis Petrik O'Malley, MD

Professor of Radiology

Director, Division of Molecular Imaging and Therapeutics University of Alabama at Birmingham School of Medicine Birmingham, Alabama



Acknowledgements

Text Editors

Nina I. Bennett, BA Sarah J. Connor, BA Tricia L. Cannon, BA Terry W. Ferrell, MS Lisa A. Gervais, BS Karen E. Concannon, MA, PhD

Image Editors

Jeffrey J. Marmorstone, BS Lisa A. M. Steadman, BS

Medical Editors

Philippe A. Tirman, MD Whitney J. Morgan, MD

Illustrations

Richard Coombs, MS Lane R. Bennion, MS Laura C. Sesto, MA

Art Direction and Design

Tom M. Olson, BA Laura C. Sesto, MA

Lead Editor

Arthur G. Gelsinger, MA

Production Coordinators

Angela M. G. Terry, BA Rebecca L. Hutchinson, BA







Sections

SECTION 1: Cardiac SECTION 2: Central Nervous System SECTION 3: Gastrointestinal SECTION 4: Lymphatic and Vascular SECTION 5: Musculoskeletal SECTION 6: Thyroid and Parathyroid SECTION 7: Thoracic SECTION 8: Urinary Tract SECTION 9: Pediatrics SECTION 10: Miscellaneous SECTION 11: Oncology SECTION 12: Nuclear Medicine Therapy SECTION 13: Physics SECTION 14: Safety

SECTION 1: CARDIAC

INTRODUCTION

4 Approach to Cardiac Imaging Paige Bennett, MD

FUNCTION AND CORONARY ARTERY DISEASE

- 6 Left Ventricular Function Paige Bennett, MD
- 10 Myocardial Infarction and Ischemia Paige Bennett, MD
- 16 Myocardial Viability Paige Bennett, MD
- 20 Right-to-Left Shunt Christopher R. McAdams, MD and Hollins Clark, MD

SECTION 2: CENTRAL NERVOUS SYSTEM

INTRODUCTION

24 Approach to Central Nervous System Imaging Akiva Mintz, MD, PhD, MHA, CFA

CEREBROSPINAL FLUID

- 26 CSF Leak Evaluation Akiva Mintz, MD, PhD, MHA, CFA and Tejaswini Vasamsetty, MD
- 30 CSF Shunt Patency Akiva Mintz, MD, PhD, MHA, CFA and Tejaswini Vasamsetty, MD
- 34 Normal Pressure Hydrocephalus Valerie E. Stine, MD and Paige Bennett, MD

DEMENTIA

- 38 Alzheimer Disease Akiva Mintz, MD, PhD, MHA, CFA and Bryan J. Neth, BS
 44 Frontoten Dementia
- Akiva Mintz, MD, PhD, MHA, CFA and Bryan J. Neth, BS48 Lewy Body Disease
- Akiva Mintz, MD, PhD, MHA, CFA and Bryan J. Neth, BS 52 Multi-Infarct Dementia

Akiva Mintz, MD, PhD, MHA, CFA and Bryan J. Neth, BS and Christopher T. Whitlow, MD, PhD, MHA

INFECTION AND INFLAMMATION

54 Brain Abscess and Encephalitis Akiva Mintz, MD, PhD, MHA, CFA and Paige Bennett, MD

MOVEMENT DISORDERS

56 Parkinson Disease Akiva Mintz, MD, PhD, MHA, CFA

VASCULAR

- 60 Brain Death Akiva Mintz, MD, PhD, MHA, CFA and Tejaswini Vasamsetty, MD
- 64 Cerebrovascular Ischemia Akiva Mintz, MD, PhD, MHA, CFA and Colin Segovis, MD, PhD

SECTION 3: GASTROINTESTINAL

INTRODUCTION

68 Approach to Gastrointestinal Imaging Paige Bennett, MD

HEPATOBILIARY

- Acute Cholecystitis and Biliary Obstruction Paula Vergara-Wentland, MD and Paige Bennett, MD
 Biliary Leak
- Paula Vergara-Wentland, MD and Paige Bennett, MD82 Functional Hepatobiliary Disease
- Paula Vergara-Wentland, MD and Paige Bennett, MD 86 Benign Solid Liver Lesions
 - Paula Vergara-Wentland, MD and Paige Bennett, MD

GASTROINTESTINAL

- **90 Gastrointestinal Bleed Localization** Paula Vergara-Wentland, MD and Paige Bennett, MD
- 96 Gastric Emptying Paula Vergara-Wentland, MD and Paige Bennett, MD

INFECTION AND INFLAMMATION

100 Abdominal Infection and Inflammatory Disease Paula Vergara-Wentland, MD and Paige Bennett, MD

SPLEEN

106 Spleen Localization

Paige Bennett, MD and Paula Vergara-Wentland, MD

SECTION 4: LYMPHATIC AND VASCULAR

INTRODUCTION

110 Approach to Lymphatic and Vascular Imaging Paige Bennett, MD

LYMPHATIC

 112 Lymphedema Christopher R. McAdams, MD and Paige Bennett, MD
 116 Sentinel Lymph Node Mapping

Christopher R. McAdams, MD and Paige Bennett, MD

VASCULAR

- 120 Large Vessel Vasculitis James Patrick Davidson, MD and Paige Bennett, MD
 122 Vascular Graft Infection
 - James Patrick Davidson, MD and Paige Bennett, MD

SECTION 5: MUSCULOSKELETAL

INTRODUCTION

128 Approach to Musculoskeletal Imaging Umesh D. Oza, MD

BONE TUMORS

- Bone Neoplasms
 Umesh D. Oza, MD and Daniel G. Hampton, MD
 Metastatic Bone Tumors
- Pushpender Gupta, MBBS

BONE DYSPLASIAS

- 142 Fibrous Dysplasia Umesh D. Oza, MD146 Paget Disease
- Umesh D. Oza, MD

BONE MINERAL DENSITY

150 Osteopenia and Osteoporosis Umesh D. Oza, MD

INFECTION AND INFLAMMATION

- **156** Arthroplasty Complication Umesh D. Oza, MD
- 160 Inflammatory Arthritis
 Umesh D. Oza, MD and Brad Perry, MD
 164 Osteomyelitis and Septic Arthritis
- Umesh D. Oza, MD and Brad Perry, MD

METABOLIC DISEASE

170 Metabolic Bone Disease Umesh D. Oza, MD and Daniel G. Hampton, MD

TRAUMA

- **174** Heterotopic Ossification Umesh D. Oza, MD
- 178 Occult Fracture Umesh D. Oza, MD and Charlotte Myers, MD
 182 Stress and Insufficiency Fracture
- Umesh D. Oza, MD

VASCULAR

186 Avascular Necrosis Umesh D. Oza, MD

- **190 Complex Regional Pain Syndrome** Umesh D. Oza, MD
- **194** Sickle Cell Disease Umesh D. Oza, MD

SECTION 6: THYROID AND PARATHYROID

INTRODUCTION

200 Approach to Thyroid and Parathyroid Imaging Paige Bennett, MD

THYROID

- 202 Graves Disease Paige Bennett, MD
- 206 Nodular Thyroid Disease Paige Bennett, MD

PARATHYROID

210 Parathyroid Adenoma Paige Bennett, MD and T. Alex McKnight, MD

SECTION 7: THORACIC

INTRODUCTION

216 Approach to Thoracic Imaging Paige Bennett, MD

INFECTION AND INFLAMMATION

- 218 Atypical Infectious Diseases Todd Michael Danziger, MD and Hollins Clark, MD
 222 Granulomatous Disease
- Todd Michael Danziger, MD and Hollins Clark, MD

LUNG PERFUSION AND VENTILATION

- **226** Pulmonary Embolism Paige Bennett, MD and G. Lance White, MD
- 230 Quantitative Lung Perfusion John M. Holbert, MD, FACR and Brad Perry, MD

SECTION 8: URINARY TRACT

INTRODUCTION

234 Approach to Urinary Tract Imaging Andrew T. Trout, MD

INFECTION AND INFLAMMATION

236 Renal Scar and Pyelonephritis Christopher R. McAdams, MD and Paige Bennett, MD

RENAL FUNCTION

- 240 Hydronephrosis Amie M. McPherson, MD and Paige Bennett, MD
 244 Vesicoureteral Reflux
- Amie M. McPherson, MD and Paige Bennett, MD 248 Renal Transplant Evaluation
- Matthew Bennett, MD and Paige Bennett, MD

252 Renovascular Hypertension

Matthew Bennett, MD and Paige Bennett, MD

SECTION 9: PEDIATRICS

INTRODUCTION

258 Approach to Pediatric Imaging Andrew T. Trout, MD

CENTRAL NERVOUS SYSTEM

260 Seizure Andrew T. Trout, MD

THYROID

264 Congenital Hypothyroidism Andrew T. Trout, MD

GASTROINTESTINAL

- 268 Gastric Motility Andrew T. Trout, MD
 272 Meckel Diverticulum
- Andrew T. Trout, MD

HEPATOBILIARY

276 Biliary Atresia Shane C. Masters, MD, PhD

INFECTION AND INFLAMMATION

- 280 Fever of Unknown Origin Andrew T. Trout, MD
- 282 Osteomyelitis and Septic Joint Andrew T. Trout, MD

MUSCULOSKELETAL

- 286 Avascular Necrosis Bimal Vyas, MD, MS and Andrew T. Trout, MD
 292 Pediatric Lower Back Pain
- Bimal Vyas, MD, MS and Andrew T. Trout, MD 296 Nonaccidental Trauma
- Bimal Vyas, MD, MS and Andrew T. Trout, MD

SECTION 10: MISCELLANEOUS

- **302** Lacrimal Complex Dysfunction Paige Bennett, MD and Zachary Allen Lindsey, MD
- **306 Salivary Gland Scintigraphy** Paige Bennett, MD

SECTION 11: ONCOLOGY

INTRODUCTION

310 Approach to Oncologic Imaging Paige Bennett, MD

BREAST

312 Benign Breast Disease Kelli Y. Ha, MD and Umesh D. Oza, MD

- 316 Primary Breast Cancer
- Umesh D. Oza, MD and Kelli Y. Ha, MD 320 Breast Cancer Staging Umesh D. Oza, MD and Kelli Y. Ha, MD

CENTRAL NERVOUS SYSTEM

- 326 Brain Metastases Paige Bennett, MD
- 328 Post-Radiation CNS Evaluation Paige Bennett, MD and Aidan Burke, MD

CUTANEOUS

330 Melanoma Paige Bennett, MD and Katarina Kesty, MD, MBA

GASTROINTESTINAL TRACT

- 334 Esophageal Cancer
 Paula Vergara-Wentland, MD and Paige Bennett, MD
 338 Gastric Cancer and Gastrointestinal Stromal Tumor
- Paula Vergara-Wentland, MD and Paige Bennett, MD 342 Colorectal and Anal Cancer Paige Bennett, MD and Charlotte Myers, MD

HEAD AND NECK

- 346 Salivary Gland Tumors Amanda Jo Lott Marcellino, MD and Paige Bennett, MD
 350 Squamous Cell Carcinoma
- Paige Bennett, MD and Aidan Burke, MD

HEPATOBILIARY

356 Hepatobiliary Malignancy Paula Vergara-Wentland, MD and Paige Bennett, MD

LYMPHOMA

- 360 Hodgkin Lymphoma
 Virginia Barnes Planz, MD and Hollins Clark, MD
 364 Non-Hodgkin Lymphoma
- 364 Non-Hodgkin Lymphoma Virginia Barnes Planz, MD and Hollins Clark, MD

MUSCULOSKELETAL

368 Multiple Myeloma Pushpender Gupta, MBBS

NEUROENDOCRINE

- 372 Carcinoid Tumor John M. Holbert, MD, FACR
- 376 Pancreatic Neuroendocrine Tumors Umesh D. Oza, MD
- **380** Pheochromocytoma and Paraganglioma Paige Bennett, MD and Charlotte Myers, MD
- 384 Medullary Thyroid Carcinoma Ashley C. Mays, MD and Paige Bennett, MD

PANCREAS

388 Pancreatic Adenocarcinoma Paula Vergara-Wentland, MD and Paige Bennett, MD

REPRODUCTIVE ORGANS

- **392** Uterine and Endometrial Cancers Paige Bennett, MD and Brad Perry, MD and Charlotte Myers, MD
- **396** Ovarian Cancer Paige Bennett, MD and Brad Perry, MD and Charlotte Myers, MD
- 400 Cervical Cancer Paige Bennett, MD and Brad Perry, MD and Charlotte Myers, MD
- 404 Vulvar and Vaginal Cancer Paige Bennett, MD and Brad Perry, MD
- 408 Prostate Cancer
 Paige Bennett, MD and Brad Perry, MD
 412 Testicular Cancer
- Paige Bennett, MD and Brad Perry, MD

THORACIC

- 416 Malignant Pleural Mesothelioma John M. Holbert, MD, FACR and Brad Perry, MD
- 420 Non-Small Cell Lung Cancer Anita Thomas, MD and Paige Bennett, MD
- 426 Small Cell Lung Cancer Anita Thomas, MD
- 430 Thymoma and Thymic Carcinoma Anita Thomas, MD
- **434** Solitary Pulmonary Nodule Pavani Thotakura, MD and Hollins Clark, MD

THYROID

440 Papillary and Follicular Thyroid Cancer Ashley C. Mays, MD and Paige Bennett, MD

URINARY TRACT

444 Renal Cell Carcinoma Paige Bennett, MD and Brad Perry, MD
448 Transitional Cell Carcinoma Paige Bennett, MD and Brad Perry, MD

PEDIATRICS

- 452 Ewing Sarcoma Andrew T. Trout, MD
- 456 Neuroblastoma Andrew T. Trout, MD460 Osteosarcoma
 - Andrew T. Trout, MD

SECTION 12: NUCLEAR MEDICINE THERAPY

- 468 I-131 Therapy for Thyroid Cancer Paige Bennett, MD
- 472 I-131 Therapy for Hyperthyroidism Paige Bennett, MD
- **476 Lymphoma Therapy** Virginia Barnes Planz, MD and Hollins Clark, MD

478 Hepatic Metastases Therapy

Trevor Downing, MD and Paige Bennett, MD and Brian Kouri, MD

482 Metastatic Bone Tumor Therapy Pushpender Gupta, MBBS

SECTION 13: PHYSICS

- 488 Basic Physics and Radionuclides Angela P. Bruner, PhD, DABR and John Bailey, MD and Umesh D. Oza, MD
 492 Nonimaging Detectors Angela P. Bruner, PhD, DABR and John Bailey, MD
 494 Gamma Camera Imaging
- Angela P. Bruner, PhD, DABR and John Bailey, MD 498 SPECT
- Angela P. Bruner, PhD, DABR and John Bailey, MD 502 **PET**
- Angela P. Bruner, PhD, DABR and John Bailey, MD506 Radiation Biology and Dose
 - Angela P. Bruner, PhD, DABR and John Bailey, MD and Umesh D. Oza, MD

SECTION 14: SAFETY

MEDICAL USE OF BYPRODUCT MATERIAL

- 512 Medical Use of Byproduct Material Umesh D. Oza, MD
- 516 General Administrative Requirements Umesh D. Oza, MD
- 520 General Technical Requirements Umesh D. Oza, MD
- 524 Radioactive Spills Umesh D. Oza, MD
- 526 Records and Reports Umesh D. Oza, MD
- 530 Written Directive Requirements Umesh D. Oza, MD

STANDARDS FOR PROTECTION AGAINST RADIATION

- 532 Standards for Protection Against Radiation Umesh D. Oza, MD
- 536 Dose Limits Umesh D. Oza. MD
- 540 Radiopharmaceutical Administration Umesh D. Oza, MD
- 542 Records and Reports Umesh D. Oza, MD
- 546 Restricted Areas and Precautionary Procedures Umesh D. Oza, MD
- 548 Surveys and Monitoring Umesh D. Oza, MD

TRANSPORTATION OF BYPRODUCT MATERIALS

550 Waste Disposal Umesh D. Oza, MD

554 Ordering, Receiving, and Opening of Packages Umesh D. Oza, MD



Diagnostic Imaging Nuclear Medicine

SECOND EDITION

This page intentionally left blank

section 1 Cardiac



Introduction

Approach to Cardiac Imaging	4
Function and Coronary Artery Disease	
Left Ventricular Function	6
Myocardial Infarction and Ischemia	10
Myocardial Viability	16
Right-to-Left Shunt	20

Nuclear Cardiac Imaging

Nuclear cardiology encompasses studies that diagnose and risk stratify coronary artery disease, myocardial infarction and hibernation, left ventricular function, and detection of rightto-left shunt.

Myocardial perfusion imaging evaluates myocardial perfusion at rest and stress, diagnosing regional or global ischemia and myocardial infarction. In 1 meta-analysis of ~ 39,000 patients, patients with normal or low-risk patterns (e.g., mild reversible perfusion abnormalities in 1 vascular territory) on myocardial perfusion imaging had a 0.6% rate of cardiac death or myocardial infarction per year. In patients with moderate or severe reversible perfusion defects, the cardiac event rate was 6% per year, a much higher rate compared with low-risk or normal scans.

Myocardial perfusion imaging provides risk stratification in symptomatic and asymptomatic patients. Patients at high risk for coronary artery disease include those with diabetes mellitus, hyperlipidemia, hypertension, and a family history of coronary artery disease. If patients with risk factors are asymptomatic, myocardial perfusion imaging provides additional clinical information predicting cardiac events. For example, in asymptomatic diabetic patients with moderate or large perfusion defects, the event rate is 2.4% per year compared with a 0.4% per year event rate in patients with mildly abnormal or normal perfusion scans.

Evidence of severe disease on myocardial perfusion imaging correlates with an annual death rate of 2.9% to 4.2%. Evidence of high-risk disease includes 2-vessel reversible perfusion defects, transient ischemic dilatation (signifying global subendocardial ischemia), and lung uptake on Tl-201 studies.

Stress protocols with myocardial perfusion imaging are tailored to the clinical situation. Exercise stress protocol utilizing the modified Bruce protocol is used when possible. Note that with myocardial perfusion imaging, exercise stress tests are less valuable in patients with left bundle branch block, as this can cause a false-positive reversible perfusion defect in the septum. Pharmacologic stress protocols can be utilized in those patients unable to exercise. Vasodilator stress agents such as adenosine, regadenoson, and dipyridamole are most commonly used, followed by dobutamine if vasodilator stress is contraindicated.

Assessment of myocardial viability can be performed using Tl-201 and F-18 FDG PET/CT. In patients found to have underperfused yet viable or hibernating myocardium, regional wall motion is expected to improve after revascularization. One meta-analysis of ~ 3,000 patients with viable segments showed a 79% reduction in annual mortality after revascularization.

Nuclear cardiac imaging also has a role in risk stratification and management of patients with heart failure. Left ventricular function can be assessed using gated acquisitions of left ventricular function on myocardial perfusion imaging or with Tc-99m-labeled red blood cells (also called MUGA). Left ventricular ejection fractions using MUGA have been shown to have less inter- and intraobserver variability than other modalities, making it especially useful in serial determinations in patients undergoing chemotherapy.

Finally, when anatomic evaluation fails to diagnose a suspected right-to-left cardiac shunt, an indirect method of

diagnosis can be obtained using nuclear medicine. If extrapulmonary localization of the pulmonary perfusion tracer Tc-99m MAA occurs, a right-to-left cardiac shunt is diagnosed.

Imaging Protocols

Myocardial Ischemia and Infarction

Cardiac radiotracers are taken up by the myocardium in proportion to cardiac blood flow. Images are obtained at rest and stress, then compared. Perfusion defects at stress that are not present at rest constitute inducible ischemia. Fixed perfusion defects at stress and rest signify myocardial infarction &/or myocardial hibernation.

Imaging protocols include single- and dual-isotope studies with Tc-99m-based perfusion agents &/or Tl-201 or PET/CT perfusion studies using Rb-82. Imaging with single-photon radiopharmaceuticals and gamma cameras is much more available clinically and less expensive than PET/CT myocardial perfusion imaging. In general, imaging with Tl-201 is used less commonly due to poorer imaging characteristics and dosimetry considerations as compared to Tc-99m-based radiopharmaceuticals.

Myocardial Viability

Myocardial viability can be assessed though Tl-201 restredistribution studies and F-18 FDG PET/CT. Tl-201 employs traditional gamma camera technology, 1 dose of radiopharmaceutical, and requires limited patient preparation. F-18 FDG PET/CT imaging of anaerobic glycolysis in hibernating, nonperfused myocardium is common, but requires recent meal and endogenous insulin response or exogenous insulin administration prior to F-18 FDG administration and PET/CT imaging. In addition, the F-18 FDG PET/CT data must be compared with a resting nuclear myocardial perfusion study, either a Tc-99m-based perfusion agent or Tl-201.

LV Function

Left ventricular function can be assessed with left ventriculography using Tc-99m-labeled red blood cells (traditionally called a MUGA scan) or gated myocardial perfusion scintigraphy, usually performed to diagnose cardiac ischemia. End-diastolic and end-systolic counts or volumes are utilized to calculate the left ventricular ejection fraction. Visual analysis of both types of studies allows for visual and quantitative analysis of regional and global left ventricular wall motion.

Right-to-Left Cardiac Shunt

To diagnose a suspected right-to-left cardiac shunt, a Tc-99m MAA pulmonary perfusion study is performed, with anterior and posterior images over the head, chest, and abdomen. In cases of right-to-left shunt, Tc-99m MAA will be present in the brain, lungs, and kidneys.

Practice Guidelines

The American Society of Nuclear Cardiology publishes clinical guidelines and quality standards for appropriate use, imaging, and reporting of nuclear cardiology studies. Content can be found online at www.asnc.org.

Selected References

1. Society of Nuclear Medicine and Molecular Imaging. ACR-SNMMI-SPR Practice Guideline for the Performance of Cardiac Scintigraphy. https://www.snmmi.org/ClinicalPractice/content.aspx?ItemNumber=6414# Cardio. Published October 1, 2009. Accessed July 31, 2015

Approach to Cardiac Imaging





(Left) This myocardial perfusion scan shows shortaxis images of the left ventricle at stress (top) and rest (bottom). Note decreased activity in the membranous septum ≥, a normal finding. (Right) This graphic shows a short-axis bull's-eye of the left ventricle depicting the 17 segments and the associated vascular supply. These segments are used when reporting nuclear cardiology studies.





(Left) Left anterior oblique raw image from a myocardial perfusion scan shows a photopenic defect around the heart ➡, corresponding to a pericardial effusion. (Right) Short-axis myocardial perfusion scan at stress (top) and rest (bottom) shows the "hurricane" sign ➡, an artifact caused by patient motion during the rest image acquisition.





(Left) Anterior and posterior Tc-99m MAA shunt study shows brain ⊇ and kidney ⊇ uptake, signifying a right-toleft cardiac shunt. (Right) Vertical long-axis F-18 FDG PET cardiac viability study shows uptake ⊇ in a segment of hibernating myocardium ⊇ on perfusion imaging. Revascularization of this region should improve myocardial contractility.

Left Ventricular Function

KEY FACTS

IMAGING

- Multiple-gated cardiac blood pool acquisition (MUGA)
 - Low inter- and intraobserver variability (< 5%)
 - High reproducibility
- Radiopharmaceutical
 - 15-25 mCi (555-925 MBq) Tc-99m pertechnetate autologous labeled red blood cells (RBCs) IV
 - In vitro RBC labeling: Highest binding of radionuclide (~ 98%)
 - o In vivo RBC labeling: > 80% binding
 - ROIs drawn around left ventricle
 - End systole, end diastole, and background
 - Heart must be in regular rhythm for optimal imaging
 - If background drawn over spleen or aorta, ejection fraction (EF) spuriously high
 - If background drawn over stomach or outside body, EF spuriously low

• High unbound Tc-99m pertechnetate with recent transfusion, renal failure, heparin therapy, some chemotherapy, other medications

DIAGNOSTIC CHECKLIST

- Evaluate raw images (cine) for study quality
 Counts, labeling, gating, views
- Compare qualitative estimation of left ventricular ejection fraction with quantitative calculation
- Comparison with previous studies important: Regions of interest should be similar
- Evaluate
 - Pericardial silhouette
 - Chamber sizes
 - o Hypo/akinesis
 - Filling defects
 - o Aneurysm
 - Ejection fraction

(Left) Left anterior oblique multiple-gated cardiac blood pool acquisition (MUGA) shows the right ventricle ⊇, pulmonary artery ⊇, aorta ⊇, and left ventricle ⊇. (Right) Left anterior oblique MUGA shows region of interest (ROI) analysis: End diastole ⊇, end systole ⊇, and background ⊇ ROIs.









IMAGING

Imaging Recommendations

- Best imaging tool
 - Multiple-gated cardiac blood pool acquisition (MUGA)
 - Tc-99m labeled autologous red blood cells (RBCs)
 - Images obtained over heart
 - Analysis of counts at end diastole and end systole \rightarrow left ventricular (LV) ejection fraction (EF)
 - o Low inter- and intraobserver variability (< 5%)
 - High reproducibility
 - Excellent correlation with cardiac catheterization ventriculography (r = 0.94)
- Protocol advice
 - Patient prep: None
 - Radiopharmaceutical: 15-25 mCi (555-925 MBq) Tc-99m pertechnetate autologous labeled RBCs IV
 - In vitro RBC labeling
 - □ Highest binding of radionuclide (~ 98%)
 - □ Safety issues with reinjection of blood products
 - Contraindicated if heparin allergy
 - In vivo RBC labeling: > 80% binding
 - High unbound Tc-99m pertechnetate levels with recent transfusion, renal failure, heparin therapy, some chemotherapy, other medications
 - o Dosimetry
 - Organ receiving largest radiation dose: Heart
 - Image acquisition
 - Patient supine
 - ECG gating
 - □ 16-32 frames per R-R interval
 - Planar images: LEAP/high-resolution collimator
 - Matrix: 64 x 64
 - Each image acquired for 300K counts or 5 min
 - Anterior view: 45° shallower than best septal LAO
 - Shows anterolateral and apical LV; right atrium and right ventricle
 - Best septal view LAO: Angle chosen that best shows septum between right and left ventricles
 Shows septal, anterolateral, posterolateral LV
 - Left lateral/LPO: 45° greater than best septal LAO
 Shows inferior, apical, anterolateral LV
 - Caudal angulation ± slanted collimator: May help separate ventricular from atrial blood pool
 - Image processing
 - Evaluate raw images (cine) for study quality:
 Counts, labeling, gating, views
 - Region of interest (ROI) analysis
 - ROIs drawn around LV: End systole, end diastole, and background
 - Manual, automatic, or semiautomatic ROI placement available
 - Avoid drawing background over spleen or aorta; EF will be spuriously high
 - Avoid drawing background over empty stomach or outside body; EF will be spuriously low
 - □ Background ~ 1/3 size of end diastole

Artifacts and Quality Control

• Heart must be in regular rhythm for optimal imaging

- o Irregular heartbeats rejected
 - Optimal: ≤ 10% irregular beats
 - Ejection fraction results less reliable if ≥ 30% irregular beats

DIFFERENTIAL DIAGNOSIS

Ischemic Dilated Cardiomyopathy

- Cardiovascular
 - Regional wall motion abnormalities in coronary artery distribution most common

Nonischemic Dilated Cardiomyopathy

- Toxic cardiomyopathy induced by chemotherapy
 Serial LVEFs most common MUGA indication
- Also: Stress-induced, infectious, genetic, peripartum, sarcoid, autoimmune, cirrhosis, end-stage renal disease

DIAGNOSTIC CHECKLIST

Image Interpretation Pearls

- Compare qualitative estimation of LVEF with quantitative calculation
 - Reprocessing may be necessary if discrepancy
- Comparison with previous studies important: ROIs should be similar
 - Reprocessing may be necessary if discrepancy

Reporting Tips

- Cardiac morphology
 - o Chamber sizes
 - o Ventricular wall thickness
 - Pericardial silhouette
 - Filling defects
- Systolic function
 - o Qualitative
 - Global LV function
 - Regional LV function
 - Hypo/akinesis, aneurysm
- Ejection fraction
 - Qualitative: Estimate from cine loop
 - Quantitative: ROI analysis of counts and calculation
 - LVEF (%): [End diastolic counts background counts] -[end systolic counts - background counts] / [end diastolic counts - background counts] x 100
- Phase image: Shows sequence of contraction of atria and ventricles
- Amplitude image: Shows magnitude of contraction of atria and ventricles
- Right ventricular EF
 - o Qualitative and quantitative analysis as with LVEF

SELECTED REFERENCES

 American College of Radiology. ACR–SNM–SPR Practice Guideline for the Performance of Cardiac Scintigraphy, Resolution 14. http://snmmi.files.cmsplus.com/docs/Cardiac_Scintigraphy_1382731812393_3.pdf. Revised 2009. Accessed July 9, 2014 (Left) Anterior MUGA shows right atrium ⊇, right ventricle ⊇, anterolateral left ventricle ⊇, and left ventricular apex ⊇. (Right) Anterior graphic of the heart shows right atrium ⊇, right ventricle ⊇, anterolateral left ventricle ⊇, and left ventricular apex ⊇.





(Left) Left anterior oblique MUGA shows septum 2, anterolateral left ventricle 3, and posterolateral left ventricle 3. Also called the best septal view, this image is commonly obtained at 45°. Caudal tilt can also assist in obtaining best view of septum. (Right) Left anterior oblique graphic of the heart shows right ventricle 3, septum 3, and left ventricle 3.



(Left) Left posterior oblique MUGA shows inferior ➡, apical ➡, and anterolateral ➡ left ventricle. Note splenic ➡ activity, normal physiologic uptake on Tc-99m pertechnetate RBC studies. (Right) Left posterior oblique graphic of the heart shows inferior ➡, apical ➡, and anterolateral ➡ left ventricle.





Left Ventricular Function

(Left) Anterior MUGA shows a large photopenic defect ≥ surrounding the heart. (Right) Left anterior oblique MUGA in the same patient shows the photopenic defect ≥ around the heart, a large pericardial effusion.





Q



(Left) Left anterior oblique MUGA shows a filling defect \blacksquare in the left ventricular apex. The differential diagnosis includes mass lesions and thrombus. Note that medical devices such as pacemakers and postmastectomy tissue expanders can cause artifactual filling defects on MUGA; however, these tend to be in different locations depending on the angle of *imaging.* (Right) *This MUGA* shows dilated left ventricle ₽ and LV dyskinesis 🔁 apparent on end-systolic images, a small LV aneurysm.



(Left) This MUGA demonstrates dilated left ventricle and global hypokinesis, evidenced by minimal excursion between end diastole ➡ and end systole ➡ in a patient with chemotherapy-induced cardiomyopathy. (Right) This MUGA shows severe biventricular enlargement ➡ in a patient with viral-induced cardiomyopathy.

KEY FACTS

DIAGNOSTIC CHECKLIST

- Raw images
 - May identify artifacts, extracardiac tracer uptake (cancer, infection, bowel), infiltration
- Study quality
 - Comment if excessive motion, poor radiotracer uptake/infiltration, technical error
- Artifacts
 - Motion, scatter, reconstruction, attenuation
- Adequacy of stress modality
 Exercise or pharmacologic
- Perfusion images: Qualitative analysis
 - o LV chamber size: Normal vs. dilated
 - 17 segment model: Describe stress/rest perfusion
 - Transient ischemic dilatation (TID): Dropout of endocardial border on stress
- Perfusion images: Quantitative analysis
 - o 17 segment model: Each segment scored on 5-pt scale

- Summed difference score: < 4 = normal; 4-8 = mildly abnormal; 9-13 = moderately abnormal; > 13 = severely abnormal
- o TID ratio: 1.12-1.36 positive for TID
- Gated images: Ejection fraction and wall motion
 Brightening and endocardial excursion = normal
 - Hypokinesis/akinesis if photopenia, lack of endocardial excursion
 - Lower limits of normal EF for MPI: 45%
 - EF overestimated if small heart size
- Conclusion
 - Positive or negative for inducible ischemia
 - Positive or negative for myocardial infarction (± periinfarct ischemia)
 - Consider possibility of hibernating myocardium, need for viability study
 - o LV function: EF and wall motion

(Left) Short axis view of the left ventricle on CT shows vascular territories supplying the myocardium. The left anterior descending artery supplies the anterior and septal walls 🖃. The left circumflex artery supplies the lateral wall 🗐. The right coronary artery supplies the inferior and inferoseptal walls 🗐. (Right) Drawing of short axis 17-segment model shows bull's-eye view of the heart for quantitative analysis.





(Left) Short axis MPI shows decreased activity in the inferolateral wall on rest \blacksquare , which is more pronounced on stress ➡ images, signifying inferolateral infarction with peri-infarct ischemia. Note the perfusion defect appears flat. (Right) Vertical long axis MPI shows inferior wall before attenuation correction \blacksquare on SPECT/CT. After attenuation correction, counts in the inferior wall 🛃 are no longer artifactually decreased by diaphragmatic/soft tissue attenuation in this obese patient.





IMAGING

General Features

- Best diagnostic clue
 - Myocardial perfusion imaging (MPI)
 - Usually Tc-99m-based perfusion agent that localizes to myocardium
 - Radiotracer injected at rest, then image
 - □ Radiotracer injected at stress, then image
 - Rest and stress images compared
 - Myocardial ischemia: Perfusion defect evident on stress images, normal perfusion on rest images
 - Acute myocardial infarction (AMI): Perfusion defect on MPI with injection within 2 hrs of pain episode
 - Chronic myocardial infarction: Fixed perfusion defect on rest and stress images
 - Hibernating myocardium: Fixed perfusion defect on rest/stress images, normal on viability images
- Location
 - Anterior/septal wall: Left anterior descending (LAD) artery
 - Lateral wall: Circumflex artery
 - Inferior wall: Posterior descending artery (PDA)
 - Right coronary artery (RCA) in 85% (right dominant)
 - Continuation of circumflex in 15% (left dominant)
 - Apex: Usually from LAD, but variable

Imaging Recommendations

- Protocol advice
- Patient preparation
 - Review for contraindications to stress test, pregnancy
 - Mostly required for stress portion of test
 NPO for 4 hrs prior to stress test
 - □ No caffeine 12 hrs prior to pharmacologic stress
- Radiopharmaceutical
 - Tc-99m sestamibi or Tc-99m tetrofosmin
 - □ Dose: 10-40 mCi (370 MBq to 1.4 GBq)
 - □ 1-day protocol: Up to 40 mCi (1.4 GBq) (10 mCi [370 MBq] for rest, 30 mCi [1.1 GBq] for stress)
 - 2-day protocol (patients > 250-275 lbs): 25-30 mCi (925 MBq to 1.1 GBq) for both rest and stress, 1 day apart
 - Dosimetry: Colon (sestamibi) and gallbladder wall (tetrofosmin) receive largest radiation dose
 - □ 6 hrs t1/2
 - Thallium-201 chloride
 - □ Dose: 2-4 mCi (74-148 MBq)
 - Rest images on dual-tracer MPI
 - Stress-rest images on Tl-201 only MPI
 - Redistribution imaging for viability
 - □ Long t1/2 (73 hrs) leads to higher dose than Tc-99m-based agents
 - Dosimetry: Kidneys receive largest radiation dose
 - Rb-82
 - Dose: 2D PET: 40-60 mCi (1.4-2.2 GBq); 3D PET: 10-20 mCi (370-740 MBq) BGO system; 30-40 mCi (1.1-1.4 GBq) LSO system
 - Generator produced
 - □ 75 sec t1/2
 - □ Cost-effective PET tracer for high-volume centers

- □ Pharmacologic stress utilized due to short t1/2
- Dosimetry: Kidneys receive largest radiation dose
- N-13 ammonia
 - Dose: 15-25 mCi (555-925 MBq)
 - PET perfusion agent
 - □ Cyclotron produced (on-site due to 9.8 min t1/2)
 - Dosimetry: Urinary bladder receives largest radiation dose
- Image acquisition: Tc-99m sestamibi and Tc-99m tetrofosmin
 - Patient position: Supine, upright/semiupright
 - Injection to imaging time: 15-60 min
 - Time between rest/stress injections: 30 min to 4 hrs
 - Collimator: Low energy, high resolution
 - 180° planar acquisition: Preferred if no attenuation correction (better spatial resolution, higher contrast, less attenuation)
 - SPECT and SPECT/CT: Preferred in obese patients, allows attenuation correction
 - Matrix: 64 x 64
 - Step and shoot or continuous acquisition
 - 60-64 projections; 20-25 sec per projection
 - ECG gate stress only or rest and stress
 - 8 frames/cycle standard
 - 140 keV with 15-20% window
- Image acquisition: Tl-201
 - Similar to Tc-99m-based tracers, except
 - □ 70-80 keV with 15-20% window
 - □ 64 projections
 - Stress-rest MPI: Image 10 min after injection for stress images; rest (redistribution) images at 3-4 hrs
 - Rest only for dual-tracer MPI: Image 10 min after injection for rest images; utilize Tc-99m-based radiotracer for stress
 - Viability: Image 10 min after injection for rest images; redistribution (viability) images at 3-4 hrs
- Image acquisition: Rb-82 and N-13 ammonia PET/CT
 - Rb-82: Image acquisition starts 1-1.5 min after injection, 5-10 min acquisition
 - N-13 ammonia: Image acquisition starts 4-5 min after injection, 10-15 min acquisition
- Attenuation correction from CT for large patients
- Image processing
 - Reconstruction using filtered backprojection or iterative reconstruction
 - Stress images usually displayed on top row, rest images on bottom row

Artifacts and Quality Control

- Motion artifact
 - Hurricane sign: Counts outside epicardial border on short axis
 - Blurred endocardial border
- Lateral wall blurring
- Scatter artifact
 - Counts scatter into inferior wall due to high bowel activity
- Reconstruction artifact
 - Photopenia in inferior wall from high bowel activity
 - Photopenia at 11 o'clock position on short-axis views on rest and stress

- Attenuation
 - Soft tissue attenuation causing fixed defects
 - Misregistration of attenuation correction map and perfusion data

DIFFERENTIAL DIAGNOSIS

Myocardial Infarction

- Normal apical thinning
- Left ventricular hypertrophy: Fixed lateral wall defect
- Soft tissue attenuation of photons: Breast (anterior wall), diaphragm (inferior wall)
- Septal hypokinesis common in absence of MI, especially after coronary artery bypass graft surgery
- Decreased activity in lateral wall on N-13 ammonia PET can be seen in healthy controls
- Myocardial hibernation: Myocardium with little/no perfusion, but viable due to anaerobic glycolysis
 25% of fixed defects are viable on viability studies

Myocardial Ischemia

- Artifactual perfusion defects on stress only (e.g., bowel activity on stress images, shift of overlying soft tissue)
- Left bundle branch block: Functional septal reversibility with exercise stress (false-positive)

Other Vascular Disease

- Vasospastic disease (Prinzmetal angina)
- Microvascular disease (e.g., diabetes mellitus, syndrome X)

PATHOLOGY

General Features

- Etiology
 - Ruptured coronary artery plaque disrupts myocardial blood supply
 - Myocardial necrosis begins in 20-30 min, spreading from subendo- to epicardium
 - o Risk factors
 - Hyperlipidemia, diabetes mellitus, hypertension, obesity, cigarette smoking, family history

CLINICAL ISSUES

Demographics

- Age
 - Men: Usually > 45 yrs
 - Women: > 55 yrs

DIAGNOSTIC CHECKLIST

Consider

- Myocardial infarction
 - Fixed perfusion defect, regional wall motion abnormalityPeri-infarct ischemia can cause chest pain
- Myocardial ischemia
 - Reversible perfusion defect on rest and stress images, no regional wall motion abnormality

Reporting Tips

- Raw images
 - Review to identify artifacts, extracardiac radiotracer uptake (breast/lung cancer, lymphoma, infection)

- Study quality
 - Comment if excessive motion, poor radiotracer uptake/infiltration, technical error
- Artifacts
 - Describe if present: Motion, scatter, reconstruction, attenuation
- Adequacy of stress modality
 - Exercise: Discuss percent age-predicted max heart rate achieved
 - Vasodilators: If infused and radiotracer injected per protocol, assume adequate stress
- Perfusion images
- Qualitative analysis
 - LV chamber size: Normal vs. dilated
 - 17 segment model: Describe perfusion defects on stress and rest using these segments
 - Transient ischemic dilatation (TID): Dropout of endocardial border on stress
- Quantitative analysis
 - Quantitative perfusion analysis
 - Computer generation of segmental perfusion scores in each of 17 segments on a 5-point scale at stress and rest (0 = normal, 4 = absent)
 - Summed stress score (SSS): Analysis of resting and stress-induced perfusion defects
 - Summed rest score (SRS): Analysis of resting perfusion defects
 - Summed difference score (SDS): SSS minus SRS; a measure of stress-induced ischemia
 - □ SDS: < 4 = normal; 4-8 = mildly abnormal; 9-13 = moderately abnormal; > 13 = severely abnormal
 - TID ratio: 1.12-1.36 correlates with multivessel disease
 TID = endocardial volume at stress / endocardial volume at rest
- Gated images
 - Wall motion
 - Normal if brightening and endocardial excursion on gated slice images
 - Hypokinesis/akinesis if photopenia, lack of endocardial excursion
 - Ejection fraction
 - Lower limits of normal for MPI: 45%
 - Overestimated if small heart size
- Conclusion
 - Positive or negative for inducible ischemia
 - Positive or negative for myocardial infarction (± periinfarct ischemia)
 - Consider possibility of hibernating myocardium, need for viability study
 - LV function: EF and wall motion

SELECTED REFERENCES

- American College of Radiology. ACR-SNMMI-SPR Practice Guideline for the Performance of Cardiac Scintigraphy. http://snmmi.files.cmsplus.com/docs/Cardiac_Scintigraphy_1382731812393_3.pdf. Revised October 1, 2009. Accessed July 18, 2014
- Struass et al. SNM Procedure Guideline for Myocardial Perfusion Imaging 3.3. http://snmmi.files.cmsplus.com/docs/Myocardial20Perfusion20Imaging203.3.pdf. June 14, 2008. Accessed July 18, 2014
- Dorbala S et al: SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med. 54(8):1485-507, 2013

Myocardial Infarction and Ischemia





(Left) Short axis MPI shows transient ischemic dilatation. Note normal endocardial border on rest \supseteq , which appears to enlarge on stress ■. This high-risk finding is due to reversible subendocardial ischemia and suggests multivessel disease. Note also the anterior \blacksquare and inferior ➡ perfusion defects at stress. (Right) Vertical long axis MPI views (same patient) show enlarged endocardial border and severe stress-induced perfusion defects involving the anterior wall ➡, inferior wall ►, and apex ►. Resting images below are normal.





(Left) Short axis MPI views in an obese patient show heterogeneous myocardium due to poor counts. The top row is prior to CT attenuation correction ₽. The bottom row is after CT attenuation correction 🛃. (Right) Short axis MPI shows high activity in adjacent bowel 🛃. Note the adjacent inferior wall shows decreased counts on rest 🄁 and normal counts on stress ➡. The bowel activity caused decreased counts in the inferior wall due to reconstruction artifact.





(Left) Short axis MPI shows extracardiac activity extending from the left ventricle ≥ due to patient motion, called the hurricane sign. With motion correction, the hurricane sign disappeared ≥. (Right) 3D MPI rendering of the left ventricle at end systole shows a dilated left ventricle with dyskinesis at the inferoseptum ≥, an apical aneurysm. (Left) Short axis MPI shows multivessel coronary disease. Anteroseptal ≥ and inferolateral ≥ perfusion defects are more evident on stress compared with rest images. (Right) Horizontal long axis MPI in the same patient shows lateral inducible ischemia ≥.





(Left) Short axis MPI bull's-eye computer analysis in the same patient shows multivessel inducible ischemia in the anteroseptum ➡, apical ➡, and inferolateral ➡ walls on stress imaging. (Right) Short axis MPI bull's-eye computer analysis in the same patient at rest shows virtually normal perfusion.











Myocardial Infarction and Ischemia





(Left) Short axis MPI shows high counts in the bowel \blacksquare due to normal radiotracer excretion. Note the relatively diminished perfusion in the inferior wall 🔊 on repeat image, confirming artifactual scatter of counts into the inferior wall. (Right) Vertical long axis MPI shows anterior inducible ischemia 🛃. Note high counts in bowel on stress images (hidden by computer processing) 🛃. Coronary artery catheterization showed no inferior wall disease, suggesting reconstruction artifact reduced counts in this area 🖘 on stress images.





(Left) Short axis MPI shows decreased counts in the left ventricle on stress ≥ that appear to improve on rest ≥. (Right) Short axis MPI in the same patient with arms up during both rest and stress acquisitions show similar perfusion patterns. Note that the images must be obtained with similar patient positioning to avoid introduction of artifacts.





(Left) Sagittal MPI raw images in an 86-year-old woman with atypical chest pain show normal myocardial uptake ➡. (Right) Sagittal MPI raw images in the same patient show abnormal uptake in the left breast ➡, a possible breast cancer. Mammographic correlation is necessary for this finding.

Myocardial Viability

KEY FACTS

TERMINOLOGY

- Myocardial viability evaluation
 - Detection of myocardial hibernation or stunning vs. necrosis/infarction in patients with ischemic cardiomyopathy

IMAGING

- Tc-99m/Tl-201 myocardial perfusion scintigraphy
 Viability present in 25% of regions called infarction
 - Viability present in up to 50% of patients with infarcted segments
- Perfusion-PET mismatch
 - Myocardial uptake of radioactive glucose analog compared with myocardial uptake of perfusion radiotracer (Tc-99m perfusion agent or Tl-201)
 - Anaerobic glucose utilization in underperfused myocardium = viability
- Tl-201 SPECT viability
- Rest-redistribution mismatch

• Delayed myocardial uptake in regions of underperfused myocardium = viability

TOP DIFFERENTIAL DIAGNOSES

- Myocardial hibernation
 - Chronic myocardial dysfunction due to chronically decreased myocardial perfusion (chronic total occlusions)
 - Regions of abnormal perfusion will show F-18 FDG utilization or redistribution on Tl-201
- Myocardial stunning
 - Temporary myocardial dysfunction due to short-term underperfusion or lack of perfusion to myocardium
 - Regions of abnormal perfusion will show F-18 FDG utilization or redistribution on Tl-201
- Myocardial infarction
 - Myocardial necrosis and remodeling (scar)
 - Regions of abnormal perfusion will show lack of F-18 FDG utilization or lack of redistribution on Tl-201

(Left) Vertical long axis F-18 FDG PET viability shows normal perfusion in the anterior wall 🔁 with associated glucose metabolism 🛃. This confirms glucose is an available substrate for hypoperfused inferior wall \square , which does not show viability on PET 🔁. (Right) Horizontal long axis F-18 FDG PET viability shows hypoperfused septum \blacksquare with glucose utilization \blacksquare signifying viability. Note that the normally perfused lateral wall 🖂 is not utilizing glucose *⊠*, signifying free fatty acids are being utilized.



(Left) Short axis F-18 FDG PET viability shows hypoperfused septum ≥ that is utilizing glucose ≥, signifying viability. Note the inferior myocardial infarction ≥ that is not viable ⊇. (Right) Vertical long axis F-18 FDG PET viability shows inferior wall perfusion ≥ and glucose metabolism ≥ mismatch. This suggests that the inferior wall will improve in contractility after revascularization.



